Effectiveness of of Sequential Left Prefrontal Repetitive Transcranial Magnetic Stimulation, With High Frequency, for Treatment-Resistant Depression, in TMS Unit, Neurcognitive Lab, Iranian National Center for Addiction Studies (INCAS), in 2011. A Randomized, Controlled Trial.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Treatment-Resistant Depression Disease
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- change (decrease) of depression according to Hamilton, Beck, BPRS questionnaires.
- Last Updated
- 14 years ago
Overview
Brief Summary
Sequential left prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS), with high frequency, for Treatment-Resistant Depression have been shown to have antidepressant effects. but doubts remain about the magnitude of previously demonstrated treatment effects.The aim of this study is To test whether daily weekday left prefrontal rTMS safely and effectively treats Resistant Depression disorder compared to sham controls.
Detailed Description
Design: Prospective, randomized, active sham-controlled (1:1 randomization), duration-adaptive design with 3 weeks of daily weekday treatment (fixed-dose phase) followed by continued blinded treatment for up to another 3 weeks in improvers. Setting: University psychiatric hospitals in Tehran including Roozbeh Hospital, Rasool Hospital and Imam Hossein General Hospital will refer clients to Iranian National Center for Addiction Studies, Tehran University of Medical Sciences. Patients: About 60 patients with unipolar nonpsychotic major depressive disorder, according to DSM-IV, resistant to treatment. INTERVENTION: We delivered rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil. Sham rTMS used a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
Investigators
Zahra Khazaeipour
Principal Investigator
Tehran University of Medical Sciences
Eligibility Criteria
Inclusion Criteria
- •DSM-IV diagnosis of major depression
- •Resistance to treatment as defined by the insufficient clinical benefit to at least one adequate medication trials
Exclusion Criteria
- •Other current Axis I disorders (except simple phobia and nicotine addiction)
- •Personal or close family history of seizure disorder
- •Ferromagnetic material in body or close to head
- •Neurologic disorder
- •Pregnancy
- •Taking medications known to lower seizure threshold (eg, theophylline)
Outcomes
Primary Outcomes
change (decrease) of depression according to Hamilton, Beck, BPRS questionnaires.
Time Frame: 3 week
The primary outcome measure for the study was score on the MADRS. The patients were assessed with the MADRS, the 17-item version of the Hamilton Depression Rating Scale (HAM-D), the Beck Depression Inventory (BDI), the Brief Psychiatric Rating Scale (BPRS), the CORE Rating of Psychomotor Disturbance (16), and the Global Assessment of Functioning (GAF) Scale (DSM-IVTR).